Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04131621
Recruitment Status : Recruiting
First Posted : October 18, 2019
Last Update Posted : April 15, 2020
Sponsor:
Information provided by (Responsible Party):
Alwin Kraemer, University Hospital Heidelberg

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022